Previous 10 | Next 10 |
Natera (NASDAQ:NTRA): Q3 GAAP EPS of -$1.63 misses by $0.34. Revenue of $158.1M (+61.2% Y/Y) beats by $6.18M. Press Release For further details see: Natera EPS misses by $0.34, beats on revenue
Natera Reports Third Quarter 2021 Financial Results PR Newswire AUSTIN, Texas , Nov. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing, today reported financial results for the third quarter ended September...
Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study Study represents the largest prospective, fully biopsy-matched cohort of dd-cfDNA for kidney transplant recipients PR Newswire AUSTIN, Texas , Nov. 3, 2021 /PRNews...
Natera Announces Third Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , Oct. 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release r...
Natera Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test Results of VALID study presented at CHEST 2021 yield an AUC of 0.91 for Prospera Lung PR Newswire AUSTIN, Texas , Oct. 18, 2021 /PRNewswire/ --...
Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by Signatera in over 1200 plasma samples PR Newswire...
Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation Results from the VALID study accepted for presentation of late breaking abstract at premier CHEST conference PR Newswire AUSTIN, Texas...
Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents PR Newswire AUSTIN, Texas , Sept. 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), is pleased that the Delaware Federal District Court ruled today that all three patents Care...
Shares of Natera Inc. (NASDAQ:NTRA) traded at a new 52-week high today of $128.80. So far today approximately 118,000 shares have been exchanged, as compared to an average 30-day volume of 585,000 shares. Natera Inc. (NASDAQ:NTRA) is currently priced 23.7% above its average consensus ana...
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria) PR Newswire AUSTIN, Texas , Sept. 17, 2021 ...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...